Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (53)	3/31/1998 1:30:00 PM
From: Biojunkie	Read Replies (1) \| Respond to of 138

According to the company's literature and press releases, they have a lead product candidate trade name Inactivin to inhibit HIV replication. Inactivin is touted as an analog of a hormone that when bioavilable (in the bloodstream) inhibits "host cellular" energy enzymes that are used by the virus to replicate. It appears that if you can slow the energy in the cells the virus uses to replicate that you can indirectly inhibit any strain of the virus and not be susceptible to the virus mutating around the treatment. Now would'nt that be somehing?????